The New Drug Approval Process: NDA Submission and Review

Recognize the content and organization of a full New Drug Application. Become familiar with: User fees and goals under the Prescription Drug User Fee Act (PDUFA); Expedited review programs; and Best practices when interacting with FDA

Daniela Drago, Partner, NDA Partners LLC

This session was recorded as part of FDLI’s Introduction to Drug Law and Regulation Course in April 2025.

Get Access

$149

+$100 for nonmembers

Buy Now

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

Virtual Learning FAQ

When will I receive my session?

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

Is my computer/mobile device compatible?

On-demand content can be played back on most devices.

Is CLE credit available?

CLE credit is not currently available for pre-recorded sessions.

Related Content

Tina Chang2025-10-10T14:31:25-04:00
Introduction to Tobacco and Nicotine Law and Regulation: Recent Developments and Hot Topics Panel Discussion

Tina Chang2025-08-22T09:21:11-04:00
Essential Vaccine Policy Updates: ACIP, CDC’s COVID-19 Guidance, and What’s Next

admin2025-08-22T09:18:37-04:00
FDA and Medical Product Oversight: Assessing Recent Changes

admin2025-06-25T16:42:07-04:00
The MAHA Agenda: Implications for Drug Pricing Reform

admin2025-06-25T16:24:49-04:00
Tariff Shake-Up: The Impact on Drug and Device Access, Costs, and Manufacturing

admin2025-05-05T09:43:50-04:00
Cosmetics and Children: Safety, Advertising, and Enforcement in the Era of Viral Products

admin2025-05-02T11:21:15-04:00
Risky Business: Addressing 2025 Drug and Device Inspections

admin2025-05-22T10:03:32-04:00
The Results Are In: How the 2024 Election Outcomes Will Impact Healthcare Policies

Kiana Walker2025-04-24T15:15:36-04:00
An Introduction to Drug Enforcement: FDA Enforcement Authorities, Tools, Violations and Initiatives

Kiana Walker2025-04-24T15:58:11-04:00
Regulation of Drug Marketing: An Introduction

Kiana Walker2025-04-24T15:55:06-04:00
Regulation of Drug Manufacturing: An Introduction

Kiana Walker2025-04-24T15:51:50-04:00
Regulation of Over-the-Counter (OTC) Drugs: An Introduction

admin2025-04-24T15:46:16-04:00
The Regulation of Biologics and Biosimilars: An Introduction

Kiana Walker2025-04-24T15:41:58-04:00
Post Approval Requirements for Drugs: An Introduction to Safety Reporting and Post-Approval Changes

Kiana Walker2024-12-20T12:27:58-05:00
An Introduction to the Abbreviated NDA (ANDA), 505(b)(2) Applications, and Patent and Exclusivity Issues

Kiana Walker2025-04-24T15:34:52-04:00
The New Drug Approval Process: NDA Submission and Review

Kiana Walker2025-04-24T15:35:54-04:00
The New Drug Approval Process: New Drug Research and Development

Kiana Walker2025-04-24T15:26:25-04:00
The New Drug Approval Process: Basic Concepts

Kiana Walker2025-04-24T15:21:03-04:00
Origins and Overview of Drug Law Regulation: An Introduction

admin2024-11-25T13:51:43-05:00
Stabilizing After the Stabilization Period: What to Expect From Further Implementation of DSCSA

Kiana Walker2025-04-14T15:07:38-04:00
International Issues for Medical Device Manufacturers: An Introduction

Kiana Walker2025-04-14T15:32:42-04:00
An Introduction to the Regulation of Promotion and Advertising for Medical Devices

Kiana Walker2025-04-14T15:03:54-04:00
FDA Authorities and Processes for the Enforcement, Compliance, and Inspection of Medical Devices

Kiana Walker2025-04-14T15:13:54-04:00
Regulatory Requirements for Medical Device Manufacturing and Quality System (QS) Regulation: An Introduction

Kiana Walker2025-04-14T15:21:04-04:00
Post Marketing Issues for Medical Devices: An Introduction

Kiana Walker2025-04-14T14:58:30-04:00
An Introduction to Coverage, Coding, and Payment of Medical Devices – Collaboration Between FDA and the Centers for Medicare and Medicaid Services (CMS)

Kiana Walker2025-04-14T15:25:14-04:00
Medical Device Premarket Approval Applications (PMA); Humanitarian Device Exemption (HDE) and Breakthrough Devices: An Introduction

Kiana Walker2025-04-14T15:29:10-04:00
An Introduction to the Medical Device Approval Process: Premarket Notification 510(k) and De Novo Requests

Kiana Walker2025-04-14T14:57:02-04:00
Medical Device Clinical Investigations: An Introduction

admin2025-04-14T14:55:27-04:00
Regulation of Digital Health Products: An Introduction

admin2025-04-14T15:36:47-04:00
An Introduction to the Regulation of Combination Products for Medical Devices

Kiana Walker2025-04-14T15:17:21-04:00
Overview of Medical Device Law and Regulation

Kiana Walker2025-10-06T11:40:06-04:00
Case Studies and Practical Implementation, an Introduction to Medical Product Advertising and Promotion

Kiana Walker2025-10-06T11:37:45-04:00
Multi-Channel, Pre-Approval, and Non-Promotional Communication, an Introduction to Medical Product Advertising and Promotion

Kiana Walker2025-10-06T11:24:48-04:00
Beyond FDA, An Introduction to Medical Product Advertising and Promotion

Kiana Walker2025-10-06T11:38:52-04:00
Core Fundamentals, an Introduction to Medical Product Advertising and Promotion

Kiana Walker2025-10-06T11:41:22-04:00
FDA Regulatory Authority, an Introduction to Medical Product Advertising and Promotion

Kiana Walker2025-10-10T13:32:43-04:00
Introduction to Tobacco and Nicotine Law and Regulation: Inspections and Enforcement

Kiana Walker2025-10-10T13:44:25-04:00
Introduction to Tobacco and Nicotine Law and Regulation: Product Compliance

Kiana Walker2025-10-10T13:57:30-04:00
Introduction to Tobacco and Nicotine Law and Regulation: The Public Heath Standard

Kiana Walker2025-10-10T13:36:42-04:00
Introduction to Tobacco and Nicotine Law and Regulation: Pathways to Market and Related FDA Processes

Kiana Walker2025-10-09T14:22:46-04:00
Introduction to Tobacco and Nicotine Law and Regulation: The Family Smoking Prevention and Tobacco Control Act (TCA) and the Deeming Regulation

admin2025-02-25T12:30:16-05:00
Hatch–Waxman at 40: A Critical Examination of its Past and Future

admin2024-10-02T10:23:12-04:00
Advancing the Mission: Former FDA Chief Counsels on FDLI’s Future as a Resource for the Bar

admin2025-03-14T16:13:51-04:00
Food and Dietary Supplement Imports and International Issues: An Introduction

admin2025-03-14T15:58:12-04:00
FDA Inspection and Enforcement Authority for Food and Dietary Supplement Manufacturers

admin2025-03-14T16:07:41-04:00
Food Advertising: An Introduction to the Federal Trade Commission and Private Rights of Action

Kiana Walker2025-03-14T16:24:22-04:00
Food Labeling: An Introduction to Nutrient Content, Health, and Other Claims

Kiana Walker2025-03-14T16:19:21-04:00
Food Labeling: An Introduction to General Requirements (Including Meat and Poultry)

admin2024-10-01T15:31:53-04:00
The Regulation of Dietary Supplements: An Introduction

Kiana Walker2025-03-14T16:05:54-04:00
Foods Developed Using Biotechnology and Animal Cell Culture Technology – US Regulatory Oversight

admin2025-03-14T15:36:56-04:00
An Introduction to U.S. Department of Agriculture Labeling, Inspection and Ingredient Approval Requirements

Kiana Walker2025-03-14T16:29:40-04:00
Food Safety: Current Good Manufacturing Practices and Related Requirements; Unintended Components/Contaminants of Food

Kiana Walker2025-03-14T16:35:37-04:00
Food Safety: An Introduction to Ingredient Preclearance/Intentional Components of Food

admin2025-03-14T15:28:46-04:00
The Regulation of Cosmetics: An Introduction

Kiana Walker2025-03-14T15:15:50-04:00
Overview of U.S. Food Law and Regulation: An Introduction

admin2024-07-19T13:37:39-04:00
The Fate of FDA Authority: Addressing Recent Supreme Court Decisions on Mifepristone, Chevron, and Beyond

admin2024-08-16T10:22:55-04:00
Veterinary Products Caselaw and Emerging Trends: An Introduction

admin2024-08-14T16:22:43-04:00
An Introduction to Animal Food, Feed, and Supplements Requirements and Challenges

admin2024-08-16T10:22:06-04:00
An Introduction to Veterinary Drug and Device Requirements and Challenges

admin2024-08-16T10:21:49-04:00
Veterinary Product Regulation: An Introduction to the Roles and Responsibilities of FDA and USDA

admin2024-08-16T10:21:36-04:00
Veterinary Products: An Introduction to the Federal Regulatory Landscape

admin2024-08-16T10:20:48-04:00
An Introduction to Laws Governing Veterinary Products

admin2024-07-19T13:26:18-04:00
An Introduction to Violations, Enforcement, and International Issues in Biologics and Biosimilars

admin2024-07-19T13:25:35-04:00
The Regulation of Biological Product Marketing: An Introduction

admin2024-07-19T13:24:14-04:00
The Regulation of Biological Product Manufacturing: An Introduction

admin2024-07-19T13:23:46-04:00
Post-Approval Pharmacovigilance of Biological Products: An Introduction

Kiana Walker2024-07-19T13:22:50-04:00
Biologics and Biosimilars: An Introduction

admin2024-07-19T13:22:17-04:00
Biological Product Approval, Vaccines, Emergency Use Authorization: An Introduction

admin2024-07-19T13:21:42-04:00
Introduction to Human Cellular and Tissue Based Products (HCT/P), Cell Therapy and Gene Therapy

admin2024-07-19T13:20:38-04:00
Regulation of Biological Product/Drug Development: An Introduction

admin2024-07-19T13:19:53-04:00
Introduction to FDA Review and Approval of Biological Products

admin2024-07-19T13:19:20-04:00
Overview of Biological Products Law and FDA’s Regulatory Processes

admin2024-07-19T13:13:49-04:00
USPTO-FDA Collaboration: Progress Towards Patently True Interagency Coordination

admin2024-07-19T12:57:18-04:00
Enhancing Engagement Opportunities and Communication with FDA

admin2024-07-19T12:51:41-04:00
Recent Rulings on Mifepristone Access: Implications for FDA and Stakeholders

admin2024-07-19T12:34:23-04:00
Meet MoCRA: Getting to Know the Modernization of Cosmetics Regulation Act

admin2024-07-19T12:32:57-04:00
Psychedelics Meet Mainstream Medicine: Overcoming Regulatory Uncertainty and Addressing Patient Safety Challenges

admin2024-07-19T12:30:04-04:00
The Drug Supply Chain Security Act: Implementation Challenges, Industry Compliance, and Best Practices

admin2024-07-19T12:28:00-04:00
Implementation of the Inflation Reduction Act: Healthcare Reform and Implications for the Pharmaceutical Industry

admin2024-07-19T12:25:37-04:00
Fundamentals of FDA Regulation of Cosmetics

admin2024-07-19T12:21:11-04:00
FDLI Book Launch—How FDA Really Works: Insights from the Experts

admin2024-07-19T12:16:34-04:00
Supply Chain Mayhem: Industry Impacts and What Can be Done

admin2024-07-19T12:15:23-04:00
Updates and Developments in Drug Compounding

admin2024-07-19T12:13:50-04:00
Essentials of Post-Inspection Actions: From FDA Notices to Criminal Prosecution

admin2024-07-19T12:12:44-04:00
Essentials of Inspection Readiness for Medical Products

admin2024-07-19T12:10:39-04:00
Essentials of FDA, DOJ, FTC Enforcement Authorities

admin2024-07-19T12:09:30-04:00
You Can’t Outsource Responsibility: Managing Quality in a Contract Manufacturing Partnership

admin2024-07-19T12:08:04-04:00
Over-the-Counter Drugs Monograph Reform – How’s it Going?

Kiana Walker2024-07-19T12:06:26-04:00
FDA’s COVID-19 Activities

Tina Chang2024-07-19T12:05:47-04:00
FDA’s Expedited Programs: Understanding Which Program Best Suits Your Product

admin2024-07-19T12:02:23-04:00
The Promise and Problem of Blockchain for Medical Products: What Lawyers Need to Know

Kiana Walker2024-07-19T11:59:18-04:00
Navigating the Complexities of Combination Product Regulation

Kiana Walker2021-11-24T09:53:29-05:00
Medical Device Clinical Investigations: An Introduction to Sponsor Responsibilities and Compliance Issues

Kiana Walker2024-07-19T11:57:10-04:00
Medical Device Manufacturer Requirements: An Introduction to Registration and Listing of Establishments

Kiana Walker2024-07-19T11:54:23-04:00
FDA and Centers for Medicare and Medicaid Services: Regulatory Considerations for Communicating and Contracting for Value

Kiana Walker2024-07-19T11:53:27-04:00
Best Practices for Drug Recalls

Kiana Walker2024-07-19T11:50:43-04:00
The Essentials of Food Science

Kiana Walker2024-07-19T11:50:11-04:00
Machine Learning for Regulatory Attorneys and English Majors

Kiana Walker2024-07-19T11:47:48-04:00
The Essentials of Tobacco and Nicotine Product Research

Kiana Walker2024-07-19T11:46:58-04:00
The Essentials of Statistics for Medical Products Lawyers

Kiana Walker2024-07-19T11:44:26-04:00
The Essentials of Clinical Trial Science

Kiana Walker2024-07-19T11:42:18-04:00
How Does FDA’s Recent Guidance on Remote Interactive Evaluations Change the Inspections Landscape?

Kiana Walker2024-07-19T11:39:26-04:00
Biologic and Biosimilar Litigation and IP Rights

Kiana Walker2024-07-19T11:38:05-04:00
The Impact of COVID-19 on the In Vitro Diagnostic Industry

Kiana Walker2024-07-19T11:35:35-04:00
Biosimilars: Regulatory Challenges and Barriers to Entry

Kiana Walker2024-07-19T11:23:55-04:00
Examining the State of Drug Importation and Drug Pricing

Kiana Walker2022-07-08T12:11:06-04:00
Compounding Drug Products Due to Supply Chain Access in Light of COVID-19

Kiana Walker2024-07-19T11:21:13-04:00
FDA’s Compounding Memorandum of Understanding with States: Questions, Concerns, and What’s Next

Kiana Walker2024-07-19T11:18:59-04:00
Continued Reliance on Foreign Drug Manufacturing and the Drug Supply Chain: Manageable Risk or Public Health Concern?

Kiana Walker2024-07-19T11:08:19-04:00
State of FDA Medical Product Manufacturer Inspections During and After COVID-19

Kiana Walker2024-07-19T11:05:20-04:00
Restarting Clinical Trials in the Wake of COVID-19

Kiana Walker2024-07-19T10:47:58-04:00
Animal Drug Compounding: FDA’s New Guidance and Impacts on Industry

Kiana Walker2022-07-08T12:14:15-04:00
COVID-19 and Beyond: Development and Implementation of Recovery Action Plans for Medical Product Manufacturers

Kiana Walker2024-07-19T10:44:30-04:00
The Long-Awaited Biologics Transition Date Has Come: What Now?

Kiana Walker2024-07-19T10:39:57-04:00
FDA’s Recent COVID-19 Guidances Facilitating Expanded Access to Certain Medical Products

Kiana Walker2024-07-19T10:37:51-04:00
What are FDA’s Tools for Responding to Public Health Emergencies Such as the Coronavirus (COVID-19)?

Kiana Walker2024-07-19T10:36:13-04:00
FDA-Related Congressional Committees: Jurisdiction, Focus, and Roles

Kiana Walker2024-07-19T10:34:35-04:00
Nicotine: What it Is, What it Does, and How to Effectively Communicate this Information to the Public

Kiana Walker2024-07-19T10:33:59-04:00
The CREATES Act Has Passed: What Does It Mean for the Generics Industry?

Kiana Walker2024-07-19T10:31:37-04:00
A Practical Guide to Bringing a Dietary Supplement to Market

Kiana Walker2024-07-19T10:28:15-04:00
Reducing Anti-Kickback Risks Associated with Medical Products

admin2020-05-19T13:52:51-04:00
Introduction to the Regulation of Cannabis-Derived Products

admin2024-07-19T10:24:30-04:00
Introduction to Product Liability Regarding FDA-Regulated Products

admin2020-05-19T13:07:31-04:00
Due Diligence: Ensuring Your Deal Doesn’t Collapse Due to Regulatory, Clinical, Quality, or Data Integrity Issues

admin2024-07-19T10:20:22-04:00
Single, Shared System Risk Evaluation and Mitigation Strategies: Opportunities and Challenges

admin2020-05-19T14:01:06-04:00
New Management Standards for Hazardous Waste Pharmaceuticals and Nicotine

admin2024-07-19T10:11:44-04:00
Patient Assistance Programs: Recent Enforcement and Best Practices

admin2024-07-19T10:09:32-04:00
Opioid Legislation: The Path Forward for FDA and DEA Webinar

admin2024-07-19T10:07:05-04:00
From Approval to Coverage – FDA and CMS Jurisdictional Lines

admin2024-07-19T10:03:52-04:00
Drug Pricing for the Food and Drug Community

admin2024-07-19T10:01:50-04:00
Organic Chemistry for the Food and Drug Community

admin2024-07-19T09:56:48-04:00
DEA Law for the Food and Drug Community

admin2024-07-19T09:55:30-04:00
Data Integrity: FDA Enforcement and Risk-Reduction Considerations

admin2024-07-19T09:50:36-04:00
Real World Evidence: Data Requirements, Utilization, and Presentation

admin2020-05-19T15:15:05-04:00
FDA, USDA, and EPA: Inter-Agency Overlap and Jurisdictional Boundaries

admin2024-07-19T09:42:22-04:00
PDUFA and BsUFA Reauthorization: Key Changes Affecting Industry and Patients

admin2024-07-19T09:37:27-04:00
REMS: Key Issues and Best Practices

admin2024-07-19T09:35:45-04:00
Compounding Still in the Mix: Title I of the DQSA, the Compounding Quality Act, Three Years Later

admin2024-07-19T09:35:55-04:00
Recent FDA Guidance Documents on Manufacturer Communications about Medical Products

admin2024-07-19T09:30:41-04:00
21st Century Cures Act

admin2024-07-19T09:24:12-04:00
Open Payments Data and the Sunshine Act: Managing the Risk of Transparency